<DOC>
	<DOC>NCT01076595</DOC>
	<brief_summary>The aim of the SEPLUS study is to evaluate the patients characteristics associated with adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in the BetaPlus program</brief_summary>
	<brief_title>Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Male or female &gt;/= 18 years old Outpatient with a confirmed diagnosis of RecurrentRemittent multiple sclerosis or patients at high risk of developing multiple sclerosis after a first demyelinating clinical event Patient who initiated Betaferon as described by SmPC less than 2 months ago. The decision of physician is clearly separated from the decision to include the patient in the study Treatment na√Øve patients before the initiation of Betaferon OR Patients having interrupted Betaferon for more than 6 months before to start again OR Patients receiving a disease modifying drug (DMD) other than Betaferon Patient with EDSS score &lt; 4 Patients approved and signed an inform consent and approved the collect of their data Contraindications and warning of the respective Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>BetaPlus program</keyword>
	<keyword>Recurrent/remittent multiple sclerosis patients</keyword>
	<keyword>Adherence to treatment regimen</keyword>
</DOC>